Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 8/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731689 | 0.91 | HDAC4 (0.35) | HDAC4OPRL1OPRM1OPRK1P2RX7 | |
| SCHEMBL9849441 | 0.89 | OPRL1 (0.35) | HDAC4OPRL1OPRM1OPRK1P2RX7 | |
| SCHEMBL19171686 | 0.85 | HDAC4 (0.39) | HDAC4OPRL1OPRM1OPRK1HSD11B1 | |
| SCHEMBL17577045 | 0.81 | HDAC4 (0.37) | HDAC4OPRL1OPRM1OPRK1HSD11B1 | |
| SCHEMBL8643255 | 0.81 | HDAC4 (0.40) | HDAC4OPRL1OPRM1OPRK1HSD11B1 | |
| SCHEMBL8643261 | 0.81 | HDAC4 (0.40) | HDAC4OPRL1OPRM1OPRK1HSD11B1 | |
| SCHEMBL9849442 | 0.81 | OPRL1 (0.32) | HDAC4OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL12733562 | 0.80 | HDAC4 (0.42) | HDAC4OPRL1OPRM1OPRK1P2RX7 | |
| SCHEMBL2909177 | 0.80 | OPRL1 (0.36) | HDAC4OPRL1OPRM1OPRK1 | |
| SCHEMBL2909182 | 0.80 | OPRL1 (0.36) | HDAC4OPRL1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4279565-A2 | THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | Merck Patent GmbH (DE) | 2023-11-22 | — | — | EP | disclosed |
| EP-3763802-B1 | THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2023-09-06 | — | — | EP | disclosed |
| US-11168255-B2 | Thiophene compound, liquid-crystalline medium and liquid-crystal display comprising the same | MERCK PATENT GMBH (DE) | 2021-11-09 | — | — | US | disclosed |
| US-20210139779-A1 | Thiophene compound, liquid-crystalline medium and liquid-crystal display comprising the same | MERCK PATENT GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| EP-3763802-A1 | THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | Merck Patent GmbH (DE) | 2021-01-13 | — | — | EP | disclosed |
| EP-3421570-B1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2020-11-11 | — | — | EP | disclosed |
| US-10774061-B2 | Liquid-crystalline medium and liquid-crystal display comprising the same | MERCK PATENT GMBH (DE) | 2020-09-15 | — | — | US | disclosed |
| EP-3460025-B1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2020-06-17 | — | — | EP | disclosed |
| EP-3460025-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | Merck Patent GmbH (DE) | 2019-03-27 | — | — | EP | disclosed |
| US-20190002430-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2019-01-03 | — | — | US | disclosed |
| EP-2279990-B1 | LIQUID CRYSTALLINE TETRACYCLIC COMPOUND HAVING FLUORINE ATOM, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2016-10-26 | — | — | EP | disclosed |
| US-20150368272-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150368272-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-24 | — | — | US | disclosed |
| US-8137583-B2 | Liquid crystal four-ring compound having fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8137583-B2 | Liquid crystal four-ring compound having fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8137583-B2 | Liquid crystal four-ring compound having fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION | 2011-04-07 | — | — | US | disclosed |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION | 2011-04-07 | — | — | US | disclosed |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION | 2011-04-07 | — | — | US | disclosed |
| EP-2279990-A1 | LIQUID CRYSTALLINE TETRACYCLIC COMPOUND HAVING FLUORINE ATOM, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2011-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002430-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | NEFM, FES, LSS | HDAC4 4786/4885OPRL1 4360/4885OPRM1 2087/4885 |
| US-10774061-B2 | Liquid-crystalline medium and liquid-crystal display comprising the same | NEFM, FES, LSS | HDAC4 4786/4885OPRL1 4360/4885OPRM1 2087/4885 |
| US-20150368272-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX3, OCIAD1, PIEZO1 | HDAC4 4248/4885OPRL1 207/4885OPRM1 93/4885 |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | ROCK1, ROCK2, LEF1 | HDAC4 2195/4885OPRL1 3448/4885OPRM1 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.